CSL Behring

News

NICE finalises support for CSL's HAE therapy Andembry

CSL Behring's Andembry can be used to prevent recurrent attacks of HAE by the NHS, following finalised guidance from reimbursement authority NICE.

News

CSL will slash headcount and hive off vaccine business

Facing declines in flu vaccination rates in the US, CSL will spin out its vaccine unit as part of a wider restructuring that will claim 3,000 jobs.

News

Germany will reimburse haemophilia gene therapy Hemgenix

Germany has agreed to reimburse CSL Behring's haemophilia B gene therapy Hemgenix with a 'unique' outcomes-based payment model.

News

EU approves CSL's once-monthly HAE drug Andembry

The EU has approved CSL's once-monthly Andembry for hereditary angioedema, challenging therapies from Takeda and Biocryst.

News

England, Denmark back CSL’s haemophilia B gene therapy

It has been a good week for CSL Behring as it rolls out haemophilia B gene therapy Hemgenix, with positive reimbursement decisions in both the UK and Denmark.

News

Pfizer offers warranty for new haemophilia B therapy Beqvez

Pfizer has said it will launch its just-approved haemophilia B gene therapy Beqvez with a warranty programme that will provide “greater certainty” to payers, after setting

NICE finalises support for CSL's HAE therapy Andembry

CSL will slash headcount and hive off vaccine business

Germany will reimburse haemophilia gene therapy Hemgenix

EU approves CSL's once-monthly HAE drug Andembry

England, Denmark back CSL’s haemophilia B gene therapy

Pfizer offers warranty for new haemophilia B therapy Beqvez

FDA approves higher Wegovy dose via 4th priority voucher

Using AI-driven synthetic personas to take your insights fur...

CSL Behring

Editor's Picks